1. Nutrition Support in Critical Illness

Quick Recap

Cross-cutting supportive-care protocol — applies across all ICU systems. Companion to ICU Discharge Criteria & Step-Down and the ABCDEF bundle referenced in the Delirium Screening & Management protocol ("E" for early mobility interacts closely with nutritional strategy). This protocol addresses the timing, route, dose, and monitoring of nutritional support in critical illness — an area with several major, recent, and genuinely practice-relevant trials not previously represented in this library.

1. Definition

Medical nutrition therapy in critical illness encompasses the timing (early vs. delayed), route (enteral vs. parenteral), and dose (calorie and protein target) of nutritional support delivered to a critically ill patient, with the goals of preserving lean body mass, supporting immune and gut barrier function, and avoiding both underfeeding and overfeeding-related harm.

Enteral nutrition (EN): nutrition delivered via the gastrointestinal tract (nasogastric, nasojejunal, or oral), preferred first-line route when the gut is functional.

Parenteral nutrition (PN): intravenous nutrition, used when EN is contraindicated, not tolerated, or insufficient to meet targets.

Permissive underfeeding: a deliberate strategy of providing less than 100% of calculated caloric requirement (commonly 40–60%) rather than targeting full caloric replacement, based on evidence that full early caloric replacement does not improve — and may worsen — outcomes in some populations (Section 22).

2. Pathophysiology

Critical illness induces a hypercatabolic, hypermetabolic state driven by stress hormones (cortisol, catecholamines, glucagon) and inflammatory cytokines, resulting in accelerated skeletal muscle breakdown (proteolysis) that is only partially attenuated — not reversed — by exogenous nutrient delivery. This distinguishes critical illness catabolism from simple starvation: in starvation, the body adapts to conserve lean mass; in critical illness, muscle breakdown continues despite adequate or even excessive feeding, because the catabolic drive is hormonally/inflammatorily mediated rather than purely substrate-deficiency-driven.

Autophagy suppression: emerging mechanistic evidence suggests early, aggressive nutrient provision (particularly amino acids/protein) may suppress autophagy — a cellular "clean-up" process implicated in clearing damaged organelles and proteins — providing a plausible biological mechanism for why early aggressive feeding has underperformed or caused harm in several major trials, in contrast to the older, purely deficit-based rationale for early full feeding.

Gut mucosal integrity: enteral feeding, even in small "trophic" amounts, is thought to help preserve gut mucosal integrity and reduce bacterial translocation risk, which is the classic mechanistic rationale for preferring EN over PN when feasible — though the clinical outcome evidence for this translating into a hard mortality benefit is less consistent than the mechanistic rationale would suggest (Section 22).

Refeeding syndrome: in patients with significant pre-existing malnutrition or prolonged starvation, reintroduction of nutrition — particularly carbohydrate — triggers an insulin surge driving intracellular shift of phosphate, potassium, and magnesium, producing life-threatening hypophosphatemia, hypokalemia, and hypomagnesemia; this is a distinct clinical entity requiring specific recognition and cautious re-feeding in at-risk patients, independent of the general dose/timing questions addressed in this protocol.

3. Immediate Stabilization (ABCDE) — Nutrition-Relevant Considerations

Airway/Breathing: confirm airway protection adequacy before initiating oral or enteral feeding; aspiration risk assessment in patients with reduced consciousness or impaired swallow.

Circulation: nutrition initiation is not a resuscitation priority — hemodynamic stabilization takes precedence; however, do not use ongoing low-dose vasopressor support alone as a reason to withhold enteral feeding once the patient is not in active, escalating shock (cross-reference NUTRIREA-2 findings, Section 11/22).

Disability: assess mental status/sedation depth as it affects aspiration risk and feeding tube tolerance.

Exposure: assess nutritional risk status on admission (Section 8) — this should happen within the first 24–48 hours, not as an afterthought once other systems are addressed.

Checklist:

4. Focused History

• Baseline nutritional status, recent weight loss, chronic malnutrition, alcohol use disorder (refeeding syndrome risk factors)
• Pre-existing GI pathology affecting EN tolerance/feasibility (short bowel, severe ileus, active GI bleeding, bowel obstruction)
• Swallow function/aspiration history if oral intake is being considered
• Renal/hepatic function affecting protein tolerance and PN component selection
• Diabetes/glycemic control history affecting feeding-related glucose management

5. Comprehensive System-wise Examination

• Abdomen: distension, bowel sounds, tenderness (informs EN feasibility and tolerance monitoring)
• General: visible muscle wasting, frailty assessment, edema (informs nutritional risk stratification and dosing-weight selection)
• Skin: pressure injury risk (nutritional status is a contributing factor)

POCUS integration: gastric antral ultrasound has been explored as a means of assessing gastric residual volume/feeding tolerance non-invasively, though this remains an emerging rather than routinely standardized practice.

6. Syndrome Identification — Reframed as Nutritional Risk/Strategy Classification

• High nutritional risk (e.g., NUTRIC score ≥5–6, significant pre-existing malnutrition, prolonged expected critical illness): may warrant more attentive protein-delivery strategies, though recent trial evidence (Section 22) tempers how aggressively this should be pursued
• Low nutritional risk: permissive underfeeding in the first week is well-supported and not associated with worse outcomes
• Refeeding syndrome risk: distinct high-risk category requiring a specific cautious-advancement protocol regardless of overall nutritional risk classification
• Shock with vasoactive support: EN and PN are both reasonable in this population per NUTRIREA-2 (Section 22); active, escalating shock remains a reason to delay feeding initiation

7. Differential Diagnosis — Reasons EN May Be Inappropriate or Poorly Tolerated

Must-not-miss contraindications to EN:

• Active, uncontrolled GI hemorrhage
• Bowel obstruction
• Severe ileus
• Hemodynamically unstable, escalating shock (distinct from stable low-dose vasopressor support, which is not itself a contraindication)

Common causes of EN intolerance:

• High gastric residual volumes (though routine GRV monitoring itself is increasingly questioned — Section 22)
• Ileus, opioid-related gut hypomotility
• Diarrhea from feed osmolarity, medication (e.g., sorbitol-containing elixirs), or C. difficile

Iatrogenic: unnecessary interruption of feeds for procedures/transport beyond what is truly required, delaying cumulative caloric/protein delivery

8. Severity/Risk Assessment

NUTRIC score: validated tool for identifying critically ill patients at high nutritional risk who may derive more benefit from adequate nutrient delivery, incorporating age, APACHE II, SOFA, comorbidities, days from hospital admission to ICU admission, and (in the modified version) IL-6.

Refeeding syndrome risk criteria: significant recent unintentional weight loss, minimal/no intake for ≥5 days, low baseline BMI, history of alcohol misuse or certain medications (insulin, chemotherapy, antacids, diuretics), pre-existing low potassium/phosphate/magnesium.

Note: the historical practice of aggressively pursuing 100% of calculated caloric/protein targets from admission, particularly in "high-risk" patients identified by NUTRIC or similar tools, has been substantially challenged by recent trial evidence (Section 22) — risk stratification remains useful for identifying patients needing closer monitoring, but should not be interpreted as a mandate for maximal early feeding.

9. Investigations

Immediate bedside: abdominal examination, bowel sound assessment

Routine labs: baseline electrolytes including phosphate, magnesium, potassium (critical for refeeding syndrome monitoring); glucose; triglycerides if PN with lipid emulsion is used; renal and hepatic function to guide protein dosing and PN component selection

Repeat frequency: daily electrolytes (more frequently — e.g., every 6–12 hours — in the first 24–48 hours for patients at refeeding syndrome risk); weekly nutritional status reassessment for prolonged ICU stays

10. Point-of-Care Ultrasound

Not a routine component of nutrition management. Gastric antral ultrasound for feeding tolerance/residual volume assessment remains an emerging, non-standardized adjunct rather than established practice; bedside muscle ultrasound (e.g., quadriceps thickness) is used in research settings to track muscle mass loss but is not yet routine clinical practice.

11. Evidence-Based Management

Route — Enteral vs. Parenteral

• Enteral nutrition remains first-line when the gut is functional and no contraindication exists, based on cost, physiological plausibility (gut mucosal integrity), and guideline consensus — though the CALORIES trial (2,400 patients) found no difference in infectious complications between early EN and early PN when PN is delivered with equivalent attention to line care and glycemic control, tempering the historical assumption that PN is inherently more dangerous
• NUTRIREA-2 trial (2,410 mechanically ventilated patients on vasoactive agents/shock): early EN vs. early PN showed no difference in 28-day or 90-day mortality or infectious complications, but the EN group had significantly more GI complications — vomiting, diarrhea, bowel ischemia (19 vs. 5 cases, p=0.007), and acute colonic pseudo-obstruction (11 vs. 3, p=0.04) — while the PN group had more hypoglycemic events
• Practical synthesis: EN remains reasonable first-line even in patients on vasoactive support who are not in active, escalating shock, but clinicians should have a lower threshold to suspect bowel ischemia in EN-fed patients on vasopressors who develop new abdominal symptoms, given this specific, statistically significant signal from NUTRIREA-2

Timing — Early vs. Late

• Early EN (within 24–48 hours) remains generally favored over delayed EN based on the broader nutrition literature, distinct from the early-PN question below
• EPaNIC trial (early vs. late PN when EN is insufficient): early PN was associated with harm — no reduction in muscle loss, and increased myosteatosis, along with more infections and delayed recovery, compared to withholding PN until day 8 when EN alone was insufficient. This directly informed the shift away from early aggressive supplemental PN

Dose — Calorie and Protein Targets: Three Converging Recent Trials

This is the area with the most significant recent practice-relevant evidence, and the direction is remarkably consistent across three major, independent, high-quality trials:

• EFFORT Protein (Heyland et al., Lancet 2023, international multicenter pragmatic registry-based RCT, high-nutritional-risk patients): higher protein dose (≥2.2 g/kg/day) vs. usual care (≤1.2 g/kg/day) — no difference in the primary outcome (time to discharge alive from hospital up to 60 days); potentially worse outcomes in the subgroup with acute kidney injury and high SOFA score (≥9) on subgroup analysis, though authors explicitly acknowledged multiplicity-of-testing concerns limiting confidence in this subgroup signal
• PRECISe trial (Bels et al., Lancet 2024, Belgium/Netherlands, mechanically ventilated patients): higher enteral protein (2.0 g/kg/day) vs. standard (1.3 g/kg/day) — no improvement in health-related quality of life or functional outcomes
• TARGET Protein trial (Summers et al., JAMA 2025, cluster-randomized crossover, 8 ICUs, Australia/New Zealand, n=3,397): augmented enteral protein (100 g protein/L formula) vs. usual protein (63 g/L) — no difference in days free of the index hospital and alive at day 90 (median difference −1.97 days, 95% CI −7.24 to 3.3); 90-day survival nearly identical (72.6% vs. 74.0%, RR 0.99)
• A pragmatic meta-analysis of 19 RCTs (1,731 patients) similarly found higher protein delivery did not significantly affect overall mortality (RR 0.91, 95% CI 0.75–1.10) or other clinical/patient-centered outcomes
• Practical synthesis: three large, independent, high-quality, recent RCTs have now converged on the same conclusion — augmenting enteral protein delivery beyond usual/moderate targets does not improve clinical or functional outcomes, and may cause harm in specific subgroups (AKI, high organ failure burden). This represents a genuine, evidence-driven departure from prior guideline recommendations that favored higher protein targets (1.2–2.0 g/kg/day range) based on weaker, largely observational evidence. Clinicians should not feel compelled to aggressively pursue high-protein targets, particularly in AKI or high-severity patients

Calorie Target — Permissive Underfeeding

• PermiT trial (Arabi et al., international multicenter RCT, medical-surgical ICU patients): permissive underfeeding (50% of calculated requirement, range 40–60%) vs. target feeding (100%, range 70–100%) — no difference in 90-day mortality or other key outcomes; a post-hoc analysis found this held across both high- and low-nutritional-risk subgroups
• NUTRIREA-3 trial: even lower early-phase targets (6 kcal/kg/day energy, 0.2–0.4 g/kg/day protein) during the first 7 days showed slightly faster readiness for ICU discharge compared to standard targets
• Practical synthesis: there is no evidence supporting aggressive pursuit of 100% caloric targets in the first week of critical illness; a permissive, gradually advancing approach is well-supported and simplifies practice without sacrificing outcomes

Gastric Residual Volume Monitoring

• Randomized trial evidence (Reignier et al., JAMA 2013) found not monitoring gastric residual volume did not increase ventilator-associated pneumonia risk compared to routine GRV monitoring — supports simplifying feeding protocols by removing routine GRV checks as a gatekeeping step for most patients, reserving GRV assessment for patients with specific clinical concern for intolerance

Practical Algorithm

1. Assess nutritional risk and refeeding syndrome risk within 24–48 hours
2. Initiate EN within 24–48 hours if gut functional and no contraindication (including in most patients on stable, non-escalating vasoactive support)
3. Advance feeds gradually toward a moderate target (not aggressively toward 100% of calculated requirement) over the first week
4. Do not routinely pursue high-protein targets (≥2 g/kg/day) — usual/moderate protein delivery is adequately supported by current evidence
5. Exercise particular caution with protein dose escalation in AKI or high-severity (SOFA ≥9) patients
6. Reserve PN for patients with EN contraindication or persistent EN insufficiency beyond approximately day 7–8, rather than early supplemental PN to "top up" inadequate EN in the first week
7. Discontinue routine GRV monitoring as a default gatekeeping practice; monitor clinically for intolerance instead
8. In refeeding-syndrome-risk patients, start feeding cautiously with close electrolyte monitoring and proactive repletion

12. Organ Support

Nutrition strategy should be integrated with, not run independently of, other organ support decisions: glycemic control targets interact with feeding rate; renal replacement therapy affects protein/fluid dosing considerations (CRRT causes amino acid losses that may modestly increase protein requirements, though this should not be conflated with the general high-protein-target question addressed above, which was neutral-to-harmful even before accounting for RRT losses); mechanical ventilation weaning readiness is not directly nutrition-dependent per current evidence but adequate nutrition supports overall recovery trajectory.

13. Disease-Specific Therapy

• Standard enteral formula: isocaloric, moderate protein content; no evidence supports routine use of specialized "immune-enhancing" formulas in unselected critically ill patients
• Refeeding syndrome prevention: start at a reduced caloric rate in at-risk patients, proactively supplement phosphate/potassium/magnesium, advance cautiously over several days with close monitoring
• Prokinetics (metoclopramide, erythromycin): reasonable for EN intolerance from gut hypomotility before escalating to PN or abandoning EN

14. Consultation Matrix

15. Monitoring Framework

• Clinical: abdominal exam, tolerance signs (distension, vomiting, new pain) — not routine GRV as a default gatekeeper
• Laboratory: daily electrolytes (more frequent in refeeding-risk patients), glucose, triglycerides if on lipid-containing PN
• Nutritional adequacy tracking: cumulative caloric/protein delivery vs. target, reviewed regularly rather than assumed from the prescribed rate alone (actual delivery commonly falls short of prescribed targets due to interruptions)
• Escalation triggers: new abdominal symptoms in an EN-fed vasopressor patient (assess for bowel ischemia), refractory intolerance despite prokinetics

16. ICU Bundle Checklist

17. Complications

Early:

• Refeeding syndrome (hypophosphatemia, hypokalemia, hypomagnesemia) if not anticipated and managed proactively
• Aspiration
• Bowel ischemia (specifically elevated risk signal in EN-fed patients on vasoactive support — NUTRIREA-2)
• Hyperglycemia from overly aggressive early feeding
• Line-related complications with PN (catheter-related bloodstream infection, thrombosis)

Late:

• Ongoing muscle wasting/ICU-acquired weakness despite nutritional support (reflects the hormonally-mediated catabolic drive that nutrition alone does not fully counteract)
• Persistent functional impairment post-ICU (post-intensive care syndrome) — not clearly improved by more aggressive protein/calorie delivery per recent trial evidence

Prevention: permissive, gradually advancing feeding strategy; proactive electrolyte monitoring in refeeding-risk patients; avoidance of early aggressive supplemental PN

Rescue: electrolyte repletion for refeeding syndrome; feed interruption and surgical evaluation for suspected bowel ischemia; prokinetics or route change for persistent intolerance

18. Escalation & De-escalation

Escalation (route/intensity): persistent EN intolerance despite prokinetics and adequate trial period → consider PN, generally not before approximately day 7–8 unless EN is entirely contraindicated from the outset.

De-escalation: transition toward oral intake as swallow function and mental status allow; discontinue supplemental PN once EN alone meets targets; taper close electrolyte monitoring once refeeding-risk window has passed without complication.

19. ICU Discharge Criteria (Nutrition-Relevant Context)

Cross-reference ICU Discharge Criteria & Step-Down protocol. Nutrition-specific consideration: adequate oral/enteral intake established, or a clear, ward-appropriate ongoing nutrition plan documented (including any ongoing PN weaning plan) before transfer — do not transfer a complex nutrition plan to a receiving unit without explicit handoff of the current strategy and monitoring needs.

20. Documentation & Medicolegal Checklist

• Nutritional risk and refeeding syndrome risk assessment documented within 24–48 hours
• Route, timing, and rationale for feeding strategy documented
• Cumulative caloric/protein delivery tracked and documented, not just prescribed rate
• Rationale for any deviation from permissive/moderate targets (e.g., decision to pursue higher protein dose) documented, given current evidence does not support this as routine practice
• Electrolyte monitoring and repletion documented for refeeding-risk patients
• Any suspected feeding-related complication (bowel ischemia, aspiration) documented with management

21. Key Guidelines

• ASPEN (American Society for Parenteral and Enteral Nutrition) 2022 guidelines: current society-level guidance, though its protein target recommendations (1.2–2.0 g/kg/day range) predate the three convergent negative high-protein trials discussed in Section 11/22 and may warrant reinterpretation in light of this newer evidence
• ESPEN (European Society for Clinical Nutrition and Metabolism) guidelines: broadly parallel framework; both major society guidelines are in a period of likely revision given the accumulated 2023–2025 trial evidence

22. Landmark Trials

23. Controversies

• The high-protein hypothesis has now been tested and substantially refuted by three independent, high-quality, convergent RCTs (EFFORT Protein, PRECISe, TARGET Protein) after years of guideline recommendations favoring higher protein targets based on weaker observational evidence — this is a genuine, evidence-driven reversal that has not yet been fully reflected in all society guidelines or institutional protocols, and represents one of the clearer recent examples in critical care of high-quality RCT evidence overturning plausible-but-unproven physiological reasoning
• AKI subgroup signal in EFFORT Protein: flagged by the trial's own authors as subject to multiplicity-of-testing concerns and should not be over-interpreted as definitively causal, but is consistent enough with biological plausibility (reduced capacity to clear nitrogenous waste) to warrant caution rather than dismissal
• EN vs. PN and bowel ischemia in shock: the NUTRIREA-2 signal for bowel ischemia with EN in vasopressor-dependent patients is statistically significant but based on small absolute numbers (19 vs. 5 events) — this should inform vigilance rather than wholesale avoidance of EN in this population, given the trial's overall neutral mortality finding
• Gastric residual volume monitoring abandonment: while trial evidence supports removing GRV as a routine default gatekeeper, this remains inconsistently implemented across institutions, and some clinicians retain GRV checks for other reasons (e.g., early detection of ileus) despite the lack of VAP-prevention rationale
• Guideline lag: current ASPEN/ESPEN protein target recommendations were largely formulated before the three convergent negative high-protein trials; institutions following guideline recommendations literally may be out of step with the most recent, highest-quality evidence until formal guideline revision occurs

24. References

1. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults (EPaNIC). N Engl J Med. 2011;365(6):506-517.
2. Harvey SE, Parrott F, Harrison DA, et al. Trial of the route of early nutritional support in critically ill adults (CALORIES). N Engl J Med. 2014;371(18):1673-1684.
3. Reignier J, Boisrame-Helms J, Brisard L, et al; NUTRIREA-2 Trial Investigators. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet. 2018;391(10116):133-143.
4. Arabi YM, Aldawood AS, Haddad SH, et al; PermiT Trial Group. Permissive underfeeding or standard enteral feeding in critically ill adults. N Engl J Med. 2015;372(25):2398-2408.
5. Heyland DK, Patel J, Compher C, et al; EFFORT Protein Trial Team. The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): a multicentre, registry-based randomised trial. Lancet. 2023;401(10376):568-576.
6. Bels JLM, van Gassel RJJ, Timmermans RGM, et al; PRECISe Study Team. Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe). Lancet. 2024;404(10453):659-669.
7. Summers MJ, Chapple LS, Karahalios A, et al; TARGET Protein Investigators. Augmented enteral protein during critical illness: the TARGET Protein randomized clinical trial. JAMA. 2025;334(4):319-328.
8. Reignier J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding. JAMA. 2013;309(3):249-256.
9. Stoppe C, Patel JJ, Zarbock A, et al. The impact of higher protein dosing on outcomes in critically ill patients with acute kidney injury: a post hoc analysis of the EFFORT Protein trial. Crit Care. 2023;27(1):399.
10. Compher C, Bingham AL, McCall M, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: ASPEN. JPEN J Parenter Enteral Nutr. 2022;46(1):12-41.
11. The Washington Manual of Critical Care, 4th ed. 2025 — nutrition support chapter.
12. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant nutrition content.